Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
The Predictive Value of Programmed Death Ligand 1 in Patients With Metastatic Renal Cell Carcinoma Treated With Immune-Checkpoint Inhibitors: A Systematic Review and Meta-AnalysisEur Urol 2020 Nov 07;[EPub Ahead of Print], K Mori, M Abufaraj, H Mostafaei, F Quhal, H Fajkovic, M Remzi, PI Karakiewicz, S Egawa, M Schmidinger, SF Shariat, KM Gust
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.